Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of Protein Misfolding Disorders, Neuropathy and Neuropathic Pain
Keppel Hesselink JM*
Department of Molecular Pharmacology, Pain Specialist, Faculty of Health, University of Witten, Germany
- *Corresponding Author:
- Keppel Hesselink JM
Faculty of Health, University of Witten/Herdecke, Germany
E-mail: [email protected]
Received date: November 21, 2016; Accepted date: December 23, 2016; Published date: December 27, 2016
Citation: Keppel Hesselink JM (2016) Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of Protein Misfolding Disorders, Neuropathy and Neuropathic Pain. J Pain Relief 6:279. doi:10.4172/2167-0846.1000279
Copyright: © 2016 Keppel Hesselink JM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Bimoclomol and arimoclomol are small new chemical entities which have been synthesized during the end of last century by a Hungarian pharmaceutical company, Biorex. Both compounds consistently increase Heat Shock Protein (HSP) expression and reduce functional as well as structural pathology in a series of animal models. The development of bimoclomol stagnated, most probably due the short half life time of the compound. Arimoclomol is currently in development for orphan disorders such as amyotrophic lateral sclerosis, the sphingolipidose Niemann- Pick type C and inclusion body myositis. Arimoclomol has high oral availability and good CNS penetration, without inducing troublesome CNS side effects. It might also be a promising compound for the treatment of diabetic neuropathy and neuropathic pain in (diabetic) neuropathy, due to its neuroprotective and analgesic properties.